Advanced Molecular Diagnostics Transform Skin Cancer Risk Stratification with Dr. Matthew Goldberg Castle Biosciences TRANSCRiPT
Release Date: 06/29/2026
Parkinson’s Disease Management Transformed by AI-Powered Longitudinal Tracking with Amy Gordon Franzen Rune Labs TRANSCRIPT
Empowered Patient Podcast
Amy Gordon Franzen, CEO of Rune Labs, developed StrivePD, a patient-facing app that supports those with Parkinson's disease by passively tracking their movements and collecting longitudinal data on tremor, gait, and activity patterns. The technology addresses a critical gap in neurodegenerative disease management by providing continuous, objective data that enables patients and clinicians to make more informed treatment decisions. There is also an AI chatbot that allows patients to interrogate their data and receive personalized insights while enabling clinicians and drug developers to...
info_outline
Parkinson’s Disease Management Transformed by AI-Powered Longitudinal Tracking with Amy Gordon Franzen Rune Labs
Empowered Patient Podcast
Amy Gordon Franzen, CEO of Rune Labs, developed StrivePD, a patient-facing app that supports those with Parkinson's disease by passively tracking their movements and collecting longitudinal data on tremor, gait, and activity patterns. The technology addresses a critical gap in neurodegenerative disease management by providing continuous, objective data that enables patients and clinicians to make more informed treatment decisions. There is also an AI chatbot that allows patients to interrogate their data and receive personalized insights while enabling clinicians and drug developers to...
info_outline
Gene Therapy for Treating Root Cause of Severe Food Allergies with Dr. Sid Kerkar AllerGene AI TRANSCRIPT
Empowered Patient Podcast
Dr. Sid Kerkar, CEO and Founder of AllerGene AI Therapeutics, is developing in vivo gene therapy for severe food allergies, where symptoms are currently treated rather than root causes. AllerGene AI is targeting mast cells, which are immune cells responsible for triggering allergic reactions, and their approach represents a significant opportunity to prevent these reactions. Unlike traditional cell therapy, this technology modifies cells within the body to recognize and eliminate armed mast cells, allowing the body to repopulate with non-reactive cells, preventing severe allergic reactions...
info_outline
Gene Therapy for Treating Root Cause of Severe Food Allergies with Dr. Sid Kerkar AllerGene AI
Empowered Patient Podcast
Dr. Sid Kerkar, CEO and Founder of AllerGene AI Therapeutics, is developing in vivo gene therapy for severe food allergies, where symptoms are currently treated rather than root causes. AllerGene AI is targeting mast cells, which are immune cells responsible for triggering allergic reactions, and their approach represents a significant opportunity to prevent these reactions. Unlike traditional cell therapy, this technology modifies cells within the body to recognize and eliminate armed mast cells, allowing the body to repopulate with non-reactive cells, preventing severe allergic reactions...
info_outline
Virtual Transitionist Model Reduces Complications after Acute Care Events with Dr. David Feldman Dimer Health TRANSCRIPT
Empowered Patient Podcast
Dr. David Feldman is the Chief Medical Officer at Dimer Health, a virtual care medical practice designed to improve patient outcomes during the critical 1-3 days following hospital discharge, outpatient surgery, or emergency room visits. The company addresses the gap in post-acute care between hospital care and primary care follow-up by proactive monitoring, medication management, and pain control. Inspired by the hospitalist model, Dimer is defining a transitionist model that is tailored to each patient's needs and home environment, intervening early on minor complications to reduce...
info_outline
Virtual Transitionist Model Reduces Complications after Acute Care Events with Dr. David Feldman Dimer Health
Empowered Patient Podcast
Dr. David Feldman is the Chief Medical Officer at Dimer Health, a virtual care medical practice designed to improve patient outcomes during the critical 1-3 days following hospital discharge, outpatient surgery, or emergency room visits. The company addresses the gap in post-acute care between hospital care and primary care follow-up by proactive monitoring, medication management, and pain control. Inspired by the hospitalist model, Dimer is defining a transitionist model that is tailored to each patient's needs and home environment, intervening early on minor complications to reduce...
info_outline
Certified Drug Label Translations in 26 Languages for Limited English Proficient Patients with Sharon Blank RxTran TRANSCRIPT
Empowered Patient Podcast
Sharon Blank, CEO of RxTran, highlights the value of certified translations of prescription dosing instructions in 26 languages to ensure that limited-English-proficient patients can understand dosing and medication risks. The organization works with pharmacies to deliver translations created by native-speaking pharmacists rather than by automated systems or untrained interpreters. As this LEP population grows, RxTran advocates for standardized, human-verified translation practices to ensure healthcare access and patient safety across all populations. Sharon explains, "So RxTran’s...
info_outline
Certified Drug Label Translations in 26 Languages for Limited English Proficient Patients with Sharon Blank RxTran
Empowered Patient Podcast
Sharon Blank, CEO of RxTran, highlights the value of certified translations of prescription dosing instructions in 26 languages to ensure that limited-English-proficient patients can understand dosing and medication risks. The organization works with pharmacies to deliver translations created by native-speaking pharmacists rather than by automated systems or untrained interpreters. As this LEP population grows, RxTran advocates for standardized, human-verified translation practices to ensure healthcare access and patient safety across all populations. Sharon explains, "So RxTran’s...
info_outline
Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki TRANSCRIPT
Empowered Patient Podcast
Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight. ...
info_outline
Using AI to Unify Healthcare HR Systems to Reduce Administrative Burden with Craig Ahrens Worki
Empowered Patient Podcast
Craig Ahrens is the CEO of Worki, a healthcare workforce management platform that aggregates fragmented HR records by unifying disparate data sources and deploying AI agents to streamline workflows. To address anxieties, the focus needs to be on reducing administrative burdens through intelligent scheduling, not on eliminating jobs. Transparency is key for employees in this integration of legacy systems with AI-powered tools, so that healthcare organizations can improve resource allocation, enhance retention, and improve patient care while maintaining human oversight. ...
info_outlineDr. Matthew Goldberg, Senior Vice President for Medical at Castle Biosciences, discusses the uncertainty clinicians face when determining treatments for skin cancer due to the limitations of traditional pathology reports. Castle's gene expression profile tests were developed to improve the accuracy of risk stratification for patients with cutaneous melanoma and high-risk cutaneous squamous cell carcinoma. These tests provide prognostic information by analyzing the tumor's RNA, offering more granular and accurate risk assessment and informing about the intensity of follow-up and long-term risk management strategies.
Matthew explains, "So this is an important topic for dermatologists who are really on the front lines of skin cancer diagnosis and management for patients who are confronting skin cancer today. I'm a board-certified dermatologist and dermatopathologist by training. And to me, I think that the core uncertainty is centered around some of the known limitations around the prognostic accuracy of pathology. That's kind of worth unpacking here, but I think what it comes down to is that dermatologists are involved in identifying concerning skin lesions, identifying and, through biopsy, taking a skin sample, and finding skin cancers."
"Dermatopathologists are the collaborative colleagues who interpret the skin biopsy samples and return the pathological diagnoses to the dermatologist. For the treating clinician, the key task is to understand the implications of the types of skin cancers identified in this process to determine the most appropriate, risk-aligned downstream management for patients with these skin cancers."
"So Castle Biosciences has developed a range of tests that are really focused on impactful skin cancers that are some of the biggest challenges for dermatologists and the patients that we serve in the clinic, specifically around cutaneous melanoma with the DecisionDx-Melanoma gene expression profile test and also high-risk cutaneous squamous cell carcinomas with the DecisionDx-SCC test."
#CastleBiosciences #SkinCancer #CancerCare #HealthcareInnovation #Dermatology #MolecularDiagnostics #PrecisionMedicine #RiskStratification #ClinicalDecisionMaking #DigitalPathology #Oncology #Melanoma #SquamousCellCarcinoma #GeneExpression #SharedDecisionMaking
